Overview
Milestone Pharma delivers end-to-end pharmaceutical testing services and medical device testing support across the full development lifecycle.
Our capabilities cover pharmaceutical packaging testing, extractables and leachables (E&L) studies, container closure integrity testing (CCIT), sterility assurance, biocompatibility testing, chemical characterization, and global regulatory support. Backed by ISO 17025-accredited laboratories and experience supporting submissions to the FDA, EU MDR, and NMPA, we help clients accelerate development with compliant, high-quality analytical data.
Services
-
Medical Device Testing and Biocompatibility Testing
-
Sterility Assurance, CCIT, and Validation Services
-
Pharmaceutical Packaging Testing, E&L, and CCIT Services
Medical Device Testing and Biocompatibility Testing
From chemical characterization to toxicological risk assessment, our medical device testing and biocompatibility testing services support ISO 10993-based biological evaluation and performance assessment across a wide range of device categories.
-
Chemical Characterization Testing
From material screening to extractable and leachable (E&L) assessment, our chemical characterization testing supports medical device biocompatibility testing under ISO 10993-17 and ISO 10993-18 by identifying extractables, leachables, and degradation products with confidence.
-
Cleaning Validation
Follows AAMI TIR30 and other standards, providing end-to-end validation from protocol design to documentation, ensuring cleaning processes meet regulatory and audit requirements.
-
Material Testing
Analyzes metals, polymers, etc. using SEM-EDS, XRD, FTIR, DSC/TGA per ISO 10993, plus failure analysis and reverse engineering.
-
Disinfectant Residue Testing
Detects residual disinfectants (EO, ECH, etc.) with ICH Q2(R1) validated methods, including toxicological assessment and regulatory submission documents for FDA/EU/NMPA.
-
Physical Characterization
Performs mechanical, thermal, and surface tests per international standards; accelerated aging per ASTM F1980 to predict device shelf life.
-
In Vitro Degradation
Evaluates degradation kinetics under physiological conditions per GB/T 16886 series; multi-point sampling until full absorption; supports absorbable devices.
-
Microbiological Testing and Antimicrobial Performance
Performed in ISO Class 5 and 7 cleanroom environments, our microbiological services include bioburden, sterility, and antimicrobial performance testing in accordance with ISO 11737, ASTM E2149, and related standards.
-
Drug-Device Compatibility
Provides drug adsorption, stability, and E&L analysis; supports FDA/EU/NMPA submissions; helps clients obtain FDA 510(k) clearance within 7 days.
-
Drug Release Mechanisms for Drug-Device Combination Products
Uses validated in vitro methods to characterize drug elution profiles for complex combination devices such as stents, bone cements, and antimicrobial dressings.
-
Computational Toxicological Risk Assessment
Employs Lhasa Suite (Derek/Sarah Nexus) with a 5000+ toxicology database to deliver toxicological assessment reports accepted by global regulators.
-
Packaging Material Compatibility
Using a QbD-based approach and an extensive extractables knowledge base, we support packaging qualification, analytical evaluation, and toxicological risk assessment for submission-ready regulatory documentation.
-
Container Closure Integrity Testing (CCIT)
Our container closure integrity testing (CCIT) services include microbial challenge, dye ingress, and helium leak testing for sterile packaging and sterile barrier systems, with helium sensitivity down to 10⁻¹⁰ atm·cc/s and alignment with USP <1207>.
Sterility Assurance, CCIT, and Validation Services
Our sterility assurance services combine filter validation, container closure integrity testing (CCIT), microbiological testing, and utility system qualification to support sterile pharmaceutical manufacturing and aseptic process control.
-
Filter Validation
Bacterial retention testing | Filter integrity testing | Adsorption testing | Extractables & leachables (E&L) analysis
-
Container Closure Integrity Testing (CCIT)
Deterministic methods: vacuum helium mass spectrometry | helium leak detection (sniffer mode) | vacuum decay | pressure decay | high-voltage leak detection (HVLD) | laser-based headspace analysis
Probabilistic methods: bacterial immersion | aerosol microbial challenge | methylene blue dye ingress | underwater bubble emission | fluorescent tracer detection
-
Microbiological Testing
Microbial limits testing | Bioburden testing | Sterility testing | Bacterial endotoxin testing | Antimicrobial effectiveness testing for sterile and non-sterile pharmaceutical products
-
Utility System Validation
Water system validation | HVAC system validation | Disinfectant validation
-
Antibiotic Potency Assays
Cylinder plate method (agar diffusion) | Turbidimetric method | Chemical and physicochemical methods (HPLC, GC)
-
Antimicrobial Effectiveness
Applicable products include: multi-dose eye drops, oral liquid preparations, cosmetics, and antimicrobial material evaluation.
Pharmaceutical Packaging Testing, E&L, and CCIT Services
From extractables and leachables (E&L) studies to container closure integrity testing (CCIT), pharmaceutical packaging testing, and global regulatory and DMF support, we provide end-to-end solutions across the full lifecycle of pharmaceutical packaging systems.
-
Packaging Compatibility Studies
Our pharmaceutical packaging testing services include extractables and leachables (E&L) studies for glass, elastomer, and polymer packaging systems, including ampoules, vials, prefilled syringes, infusion bags, and ophthalmic containers, supported by QbD and PQRI-based strategies.
-
Process Component Compatibility
Dual risk assessment per USP <1665> and BPOG. Identifies extractables for fluid transfer, filtration, container closure, and metal systems.
-
Drug Delivery Device Compatibility
E&L studies for injection, infusion, catheters, and combination products. QbD-based full lifecycle risk management. Materials: glass, polymer (PVC, TPU, PP), elastomer, SS316L.
-
Container Closure Integrity Testing (CCIT)
We offer 11 validated CCIT approaches, including helium leak detection, vacuum and pressure decay, HVLD, microbial challenge, and dye ingress, to support sterile packaging evaluation for vials, prefilled syringes, biologics, and other high-value products.
-
Physicochemical Testing
Rubber: particle shedding, puncture force, sealing, heavy metals. Glass: thermal expansion, B₂O₃ content, hydrolytic resistance, light transmittance. Metal: coating adhesion, strength, elemental impurities.
-
Registration and DMF Filing
Global registration and DMF filing for pharmaceutical packaging materials. End-to-end services from strategy to approval. FDA and NMPA approvals obtained.
Feature Strengths
-
Regulatory Insight for Pharmaceutical and Medical Device Testing
Our team brings deep knowledge of global regulatory expectations and industry guidance for pharmaceutical packaging testing, container closure integrity testing, sterility assurance, biocompatibility testing, and product quality studies.
-
Advanced Analytical and Testing Capability
From chemical characterization and extractables and leachables testing to CCIT and microbiological testing, we deliver reliable, defensible data for complex pharmaceutical and medical device programs.
-
Full-Lifecycle Support from Development to Registration
We support pharmaceutical testing services and medical device testing projects from early development and method establishment through registration, commercialization, and post-approval change management.
FAQ
-
What is the Maximum Allowable Leakage Limit (MALL)?
The MALL is the leak rate that corresponds to the maximum leak size that could compromise sterility — typically considered to be approximately 0.1–1.0 μm for most sterile products. Our vacuum decay method (LOD 1 μm) can reliably detect leaks at or below the MALL for most applications.
-
Can you validate a CCIT method for my specific packaging?
Yes. We develop and validate CCIT methods tailored to your specific packaging configuration. Validation includes sensitivity studies (spiked samples with known defect sizes), specificity testing, and correlation to microbial challenge data per USP <1207> recommendations.
-
How do I choose the right CCIT method for my product?
The right CCIT method depends on your package type, product characteristics, required sensitivity, and regulatory expectations. Deterministic methods such as vacuum decay, helium leak detection, and HVLD are often preferred for their reproducibility and sensitivity, while challenge-based methods can support development or correlation studies.
-
What is the difference between deterministic and probabilistic container closure integrity testing (CCIT)?
Deterministic container closure integrity testing (CCIT) methods such as vacuum decay, pressure decay, and helium leak detection produce quantitative, reproducible results with defined sensitivity limits. Probabilistic methods such as microbial challenge and dye ingress produce pass/fail outcomes with greater statistical variability. USP <1207> generally prefers deterministic methods for stronger scientific assurance.
-
How long does a pharmaceutical packaging E&L study usually take?
A typical pharmaceutical packaging extractables and leachables (E&L) study takes about 8 to 16 weeks, depending on the packaging configuration, material complexity, study design, analytical method requirements, and toxicological risk assessment scope.
-
What is included in your extractables and leachables testing database?
Our proprietary database contains over 1000 known packaging extractables with their chemical structures, analytical detection methods, and toxicological data. This enables rapid identification of detected compounds and streamlines the toxicological risk assessment process.
-
What is the difference between extractables and leachables in pharmaceutical packaging testing?
Extractables are compounds that can be pulled from packaging materials under aggressive laboratory conditions. Leachables are compounds that actually migrate into the drug product under normal storage or use conditions. In practice, extractables studies define potential risk, while leachables studies confirm real product exposure.
Discuss My Project
Speak with an expert about your upcoming project to see how we can help you.